Related Experiment Video
Updated: May 16, 2026
Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
Published on: May 3, 2017
Targeting mGluR2/3 Signaling With LY341495 Restores Dentate Gyrus Function and Cognitive Performance in a Male Mouse
Cui-Ping Chen1, Ting Zhang2, Er-Deng E2
1Cerebrovascular Disease Center, Ningbo Key Laboratory of Nervous System and Brain Function, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
Background:
Aberrant metabotropic glutamate receptor 2/3 (mGluR2/3) signaling has been implicated in the synaptic and cognitive deficits observed in Alzheimer's disease (AD), yet the underlying regulatory mechanisms remain unclear. This study investigated the therapeutic potential of LY341495, a selective mGluR2/3 antagonist, in APP/PS1 transgenic mice, a widely used AD model.
Methods:
Male APP/PS1 mice were treated with the selective mGluR2/3 antagonist LY341495. Cognitive performance was evaluated using behavioral tests. Hippocampal dentate gyrus (DG) alterations were examined by immunohistochemistry and electrophysiology, including analyses of mGluR2/3 expression, excitatory synaptic activity, adult neurogenesis, calbindin expression, and amyloid-β plaque burden.
Results:
APP/PS1 mice exhibited pathological upregulation of mGluR2/3 in the DG, accompanied by altered presynaptic glutamatergic transmission, reduced neurogenesis, decreased calbindin expression, and deficits in recognition and spatial memory. LY341495 treatment attenuated the aberrant mGluR2/3 upregulation, enhanced excitatory synaptic activity, and improved calbindin levels and neurogenesis in the DG. Importantly, these changes were associated with significant reductions in DG amyloid-β plaque burden and marked improvements in cognitive performance.
Conclusions:
This study highlights the novelty of linking mGluR2/3 inhibition to the restoration of calcium-buffering capacity, as reflected by calbindin expression and neurogenesis, processes critical for DG plasticity and resilience. These findings underscore the therapeutic potential of LY341495 as a novel intervention targeting mGluR2/3 signaling in AD.
Insights
Targeting metabotropic glutamate receptor 2/3 (mGluR2/3) with LY341495 improved cognition and reduced amyloid plaques in Alzheimer
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Aberrant metabotropic glutamate receptor 2/3 (mGluR2/3) signaling is linked to synaptic and cognitive deficits in Alzheimer's disease (AD).
- The precise regulatory mechanisms driving these deficits remain unclear.
- This study explores the therapeutic potential of LY341495, a selective mGluR2/3 antagonist, in a mouse model of AD.
Purpose of the Study:
- To investigate the therapeutic potential of LY341495, a selective mGluR2/3 antagonist, in APP/PS1 transgenic mice.
- To examine the effects of LY341495 on cognitive performance and hippocampal dentate gyrus (DG) alterations in AD mice.
Main Methods:
- APP/PS1 mice were administered LY341495.
- Cognitive function was assessed using behavioral tests.
- Hippocampal DG was analyzed for mGluR2/3 expression, synaptic activity, neurogenesis, calbindin levels, and amyloid-β plaques via immunohistochemistry and electrophysiology.
Main Results:
- APP/PS1 mice showed increased mGluR2/3, impaired synaptic function, reduced neurogenesis, lower calbindin, and cognitive deficits.
- LY341495 treatment normalized mGluR2/3 levels, improved synaptic activity, enhanced calbindin and neurogenesis in the DG.
- These improvements correlated with reduced amyloid-β burden and enhanced cognitive performance in AD mice.
Conclusions:
- Inhibition of mGluR2/3 signaling by LY341495 restores calcium-buffering capacity via calbindin and neurogenesis.
- These processes are crucial for DG plasticity and resilience in Alzheimer's disease.
- LY341495 shows promise as a novel therapeutic agent targeting mGluR2/3 signaling in AD.
